Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Myeloid Reconstitution

The CD34+90+ cell dose does not predict early engraftment of autologous blood stem cells as well as the total CD34+ cell dose

Bone Marrow Transplantation volume 25, pages 435–440 (2000)Cite this article

Abstract

CD90 or Thy-1 is an antigen co-expressed with CD34+ on putative immature hematopoietic stem cells. Peak mobilization of CD34+90+ cells into the blood occurs a few days earlier than peak mobilization of total CD34+ cells. Because it is not known which cell type best correlates with engraftment, the optimal timing of apheresis remains unclear. The purpose of the study was to determine if the CD34+90+ cell dose predicts engraftment of autologous blood stem cells independent of the total CD34+ cell dose/kg, the dose of other CD34+ cell subsets (CD34+33−, CD34+38−, CD34+41+), or various clinical factors. Data were analyzed on 125 consecutive patients ranging in age from 19 to 66 years (median 46) who underwent autologous blood stem cell transplantation (ABSCT) for breast cancer (54), lymphoma (59), or other malignancies (12). By univariate analysis, neutrophil (⩾0.5 × 109/l) and platelet (⩾20 × 109/l or ⩾100 × 109/l) engraftment correlated better with the total CD34+ cell dose than with the CD34+90+ cell subset. Using Cox proportional hazards models, factors independently associated with both neutrophil engraftment (⩾0.5 × 109/l) and platelet engraftment (⩾20 × 109/l and ⩾100 × 109/l) were higher total CD34+ dose/kg and high-dose regimen (melphalan-containing slower than other regimens). In conclusion, the total CD34+ dose/kg was a better predictor of hematopoietic engraftment following ABSCT than the dose of any CD34+ subset, including CD34+90+ cells. Apheresis should continue to be timed according to peak CD34+ levels. Bone Marrow Transplantation (2000) 25, 435–440.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. To LB, Haylock DN, Simmons PJ et al. The biology and clinical use of blood stem cells Blood 1997 89: 2233–2258

    CAS  Google Scholar 

  2. Sutherland DR, Anderson L, Keeney M et al. The ISHAGE guidelines for CD34+ cell determination by flow cytometry J Hematother 1996 5: 213–226

    Article  CAS  Google Scholar 

  3. Zimmerman TM, Lee WJ, Bender JG et al. Quantitative CD34+ analysis may be used to guide peripheral-blood stem cell harvest Bone Marrow Transplant 1995 9: 439–444

    Google Scholar 

  4. Krause DS, Fackler MJ, Civin CI et al. CD34: structure, biology, and clinical utility Blood 1996 87: 1–13

    CAS  PubMed  Google Scholar 

  5. Lansdorp PM, Sutherland HJ, Eaves CJ . Selective expression of CD45 isoforms on functional subpopulations of CD34+ hematopoietic cells from human bone marrow J Exp Med 1990 172: 363–366

    Article  CAS  Google Scholar 

  6. Terstappen LWMM, Huang S, Safford M et al. Sequential generation of hematopoietic colonies derived from single nonlineage-committed CD34+38− progenitor cells Blood 1991 77: 1218–1227

    CAS  PubMed  Google Scholar 

  7. Bernstein ID, Leary AG, Andrews RG et al. Blast colony-forming cells and precursors of colony-forming cells detectable in long-term marrow culture express the same phenotype (CD33-CD34+) Exp Hematol 1991 19: 680–682

    CAS  PubMed  Google Scholar 

  8. Pierelli L, Teofili L, Menichella G et al. Further investigations on the expression of HLA-DR, CD33, and CD13 surface antigens in purified bone marrow and peripheral blood CD34+ hematopoietic progenitor cells Br J Haematol 1994 84: 24–30

    Article  Google Scholar 

  9. Brandt J, Baird N, Lu L et al. Characterization of a human hematopoietic progenitor cell capable of forming blast cell containing colonies in vitro J Clin Invest 1988 82: 1017–1027

    Article  CAS  Google Scholar 

  10. Buhring HJ, Asenbauer B, Katrilaka K et al. Sequential expression of CD34 and CD33 antigens on myeloid colony-forming cells Eur J Haematol 1989 42: 143–149

    Article  CAS  Google Scholar 

  11. Loken MR, Shah VO, Dattilio KL et al. Flow cytometric analysis of human bone marrow. I. Normal erythroid development Blood 1987 69: 255–263

    CAS  PubMed  Google Scholar 

  12. Loken MR, Shah VO, Dattilio KL et al. Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development Blood 1987 70: 1316–1324

    CAS  PubMed  Google Scholar 

  13. Debili N, Issaad C, Masse JM et al. Expression of CD34 and platelet glycoproteins during human megakaryocytic differentiation Blood 1992 80: 3022–3035

    CAS  PubMed  Google Scholar 

  14. Vainchenker W, Deschamps JF, Bastin JM et al. Two monoclonal antiplatelet antibodies as markers of human megakaryocyte maturation: immunofluorescent staining and platelet peroxidase detection in megakaryocyte colonies and in in vivo cells from normal and leukemic patients Blood 1982 59: 514–521

    CAS  PubMed  Google Scholar 

  15. Stewart DA, Guo D, Luider J et al. Factors predicting engraftment of autologous blood stem cells: CD34+ subsets inferior to the total CD34+ cell dose Bone Marrow Transplant 1999 23: 1237–1243

    Article  CAS  Google Scholar 

  16. Derksen MW, Rodenhuis S, Dirkson MKA et al. Subsets of CD34+ cells and rapid hematopoietic recovery after peripheral-blood stem cell transplantation J Clin Oncol 1995 13: 1922–1932

    Article  Google Scholar 

  17. Millar BC, Millar JL, Shepherd V et al. The importance of CD34+/CD33− cells in platelet engraftment after intensive therapy for cancer patients given peripheral blood stem cell rescue Bone Marrow Transplant 1998 22: 469–475

    Article  CAS  Google Scholar 

  18. Copelan EA, Ceselski SK, Ezzone SA et al. Mobilization of peripheral-blood progenitor cells with high dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma, and Hodgkin's disease J Clin Oncol 1997 15: 759–765

    Article  CAS  Google Scholar 

  19. Pecora AL, Preti RA, Gleim GW et al. CD34+33− cells influence days to engraftment and transfusion requirements in autologous blood stem-cell recipients J Clin Oncol 1998 16: 2093–2104

    Article  CAS  Google Scholar 

  20. Gonzalez-Requejo A, Madero L, Diaz MA et al. Progenitor cell subsets and engraftemnt kinetics in children undergoing autologous peripheral blood stem cell transplantation Br J Haematol 1998 101: 104–110

    Article  CAS  Google Scholar 

  21. Craig W, Kay R, Cutler RL, Lansdorp PM . Expression of Thy-1 on human hematopoietic progenitor cells J Exp Med 1993 177: 1331–1342

    Article  CAS  Google Scholar 

  22. Humeau L, Bardin F, Maroc C et al. Phenotypic, molecular and functional characterisation of human peripheral blood CD34+/Thy1+ cells Blood 1996 87: 949–955

    CAS  PubMed  Google Scholar 

  23. Haas R, Mohle R, Murea S et al. Characterisation of peripheral blood progenitor cells mobilised by cytotoxic chemotherapy and recombinant granulocyte colony-stimulating factor J Hematother 1994 3: 323–330

    Article  CAS  Google Scholar 

  24. Murray L, Chen B, Galy A et al. Enrichment of human hematopoietic stem cell activity in the CD34+Thy-1+Lin− subpopulation from mobilized peripheral blood Blood 1995 85: 368–378

    CAS  PubMed  Google Scholar 

  25. Stewart AK, Keating IA, Anania S et al. Optimising the CD34+ and Thy-1+ stem cell content of peripheral blood collections Exp Hematol 1995 23: 1619–1627

    CAS  PubMed  Google Scholar 

  26. Tsuchiya S, Kikuta A, Shimizu Y et al. Decrease in Thy-1 expression on peripheral CD34 positive cells induced by G-CSF mobilization. The Tohoku Children Leukemia Study Group Tohoku J Exp Med 1997 182: 157–162

    Article  CAS  Google Scholar 

  27. Stewart DA, Guo D, Morris D et al. Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens Bone Marrow Transplant 1999 23: 111–117

    Article  CAS  Google Scholar 

  28. Bensinger W, Appelbaum F, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells J Clin Oncol 1995 13: 2547–2555

    Article  CAS  Google Scholar 

  29. Weaver CH, Hazelton B, Birch R et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral-blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy Blood 1995 10: 3961–3969

    Google Scholar 

Download references

Acknowledgements

We thank Jan McLaughlin for data collection and management.

Author information

Authors and Affiliations

  1. Department of Medicine, Foothills Hospital, and University of Calgary, Calgary, Alberta, Canada

    DA Stewart, D Morris, A Chaudhry, C Brown, JA Russell & S Gluck

  2. Department of Epidemiology, Foothills Hospital, and University of Calgary, Calgary, Alberta, Canada

    D Guo

  3. Department of Flow Cytometry, Foothills Hospital, and University of Calgary, Calgary, Alberta, Canada

    J Luider

  4. Department of Pathology, Foothills Hospital, and University of Calgary, Calgary, Alberta, Canada

    I Auer

  5. Department of Apheresis, and Alberta Bone Marrow Transplant Program, Tom Baker Cancer Centre, Foothills Hospital, and University of Calgary, Calgary, Alberta, Canada

    J Klassen

Authors
  1. DA Stewart
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Luider
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I Auer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J Klassen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D Morris
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A Chaudhry
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. JA Russell
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. S Gluck
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stewart, D., Guo, D., Luider, J. et al. The CD34+90+ cell dose does not predict early engraftment of autologous blood stem cells as well as the total CD34+ cell dose. Bone Marrow Transplant 25, 435–440 (2000). https://doi.org/10.1038/sj.bmt.1702171

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702171

Keywords

This article is cited by

Search

Advanced search

Quick links